A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma

Published: 04-03-2015
Last updated: 15-04-2024

Primary Objective- To evaluate if daratumumab can effectively decrease M protein in subjects with intermediate or high-risk SMM as assessed by CR rate- To determine if daratumumab reduces the progression/death rate in subjects with intermediate or...

Ethical review	Approved WMO
Status	Recruiting
Health condition type	Haematopoietic neoplasms (excl leukaemias and lymphomas)
Study type	Interventional

Summary

ID

NL-OMON54517

Source
ToetsingOnline

Brief title
54767414SMM2001 / Centaurus

Condition

- Haematopoietic neoplasms (excl leukaemias and lymphomas)

Synonym
Smoldering Multiple Myeloma - asymptomatic plasma cell disorder

Research involving
Human

Sponsors and support

Primary sponsor: Janssen-Cilag
Source(s) of monetary or material Support: Door de opdrachtgever.

Intervention

Keyword: Daratumumab, Multiple Myeloma, Smoldering

Outcome measures

Primary outcome

To determine the best dose regimen of treatment with daratumumab in Smoldering

Multiple Myeloma patients.

Secondary outcome

N/A

Study description

Background summary

Two hypotheses will be tested:
1. The CR rate at 6 months after the last subject is randomized is greater than or equal to 35%.
2. The disease progression [PD]/death rate one year after the last subject is randomized is less than or equal to 0.185.

Study objective

Primary Objective
- To evaluate if daratumumab can effectively decrease M protein in subjects with intermediate or high-risk SMM as assessed by CR rate
- To determine if daratumumab reduces the progression/death rate in subjects with intermediate or high-risk SMM

Secondary Objectives
The secondary objectives are:
- To evaluate preliminary efficacy, including Overall Response Rate (ORR) and progressionfree survival (PFS)
- To evaluate the minimal residual disease (MRD) negative rate
- To evaluate the pharmacokinetics and immunogenicity of daratumumab
- To assess the safety profile of daratumumab given in 3 different dosing schedules
- To determine if daratumumab has an effect on QT interval

Study design

This is a randomized study to compare three different dosing schedules of daratumumab.

Intervention

Refer to table 3 on page 18 of the protocol.

Study burden and risks

The adverse events observed mostly related to the administration of daratumumab were fever, high protein levels in the urine, fatigue, infusion-related reactions, diarrhea, cough, infection of the nose, sinuses and/or throat, nausea, dizziness, colds and back pain. Refer to the patient information sheet for a complete overview.

Contacts

Public
Janssen-Cilag

Graaf Engelbertlaan 75
Breda 4837 DS
NL
Scientific
Janssen-Cilag

Graaf Engelbertlaan 75
Breda 4837 DS
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

- diagnosis of smoldering multiple myeloma (SMM) for less than 5 years , - have a confirmed diagnosis of intermediate or high-risk SMM, and an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

Exclusion criteria

1. Active multiple myeloma, requiring treatment as defined by the study protocol
2. Primary systemic AL (immunoglobulin light chain) amyloidosis
3. Prior or concurrent exposure to any of the following: approved or investigational treatments for SMM or/and multiple myeloma, daratumumab or other anti CD-38 therapies, treatment with bone-protecting agents (eg, bisphosphonates, denosumab) or corticosteroids with a dose not exceeding 10 mg prednisone per day or equivalent are only allowed if given in a stable dose and for a nonmalignant condition, or received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 4 weeks before Cycle 1, Day 1
4. history of malignancy (other than SMM) within 3 years before the date of randomization, except for the following if treated and not active: basal cell or nonmetastatic squamous cell carcinoma of the skin, cervical carcinoma in situ, ductal carcinoma in situ of breast, or International Federation of Gynecology and Obstetrics (FIGO) Stage 1 carcinoma of the cervix
5. Known chronic obstructive pulmonary disease (COPD) OR moderate or severe persistent asthma within the past 2 years
6. Subject is known to be seropositive for human immunodeficiency virus (HIV) OR known to have history of hepatitis C OR known to be seropositive for hepatitis B
7. Any concurrent medical or psychiatric condition or disease (eg, autoimmune disease, active systemic disease, myelodysplasia) that is likely to interfere with the study procedures or results, or that in the opinion of the investigator, would constitute a hazard for participating in this study
8. Subject has clinically signifcant cardiac disease.
9. Screening QT interval (QTcF) > 470 msec.

Study design

Design

Study phase:	2
Study type:	Interventional
Intervention model:	Parallel
Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Recruiting
Start date (anticipated):	04-11-2015
Enrollment:	6
Type:	Actual

Medical products/devices used

Product type:	Medicine
Brand name:	Daratumumab
Generic name:	Daratumumab
Registration:	Yes - NL outside intended use

Ethics review

Approved WMO Date:	04-03-2015
Application type:	First submission
Review commission:	METC Amsterdam UMC
Approved WMO Date:	12-05-2015
Application type:	First submission
Review commission:	METC Amsterdam UMC
Approved WMO Date:	28-08-2015
Application type:	Amendment

Review commission:	METC Amsterdam UMC
Approved WMO Date:	10-09-2015
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	16-09-2015
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	19-11-2015
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	20-01-2016
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	01-04-2016
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	06-04-2016
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	27-07-2016
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	17-08-2016
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	22-12-2016
Application type:	Amendment

Review commission:	METC Amsterdam UMC
Approved WMO Date:	17-03-2017
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	22-03-2017
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	26-04-2017
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	02-08-2017
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	08-08-2017
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	16-01-2018
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	01-02-2018
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	19-02-2018
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	20-02-2018
Application type:	Amendment

Review commission:	METC Amsterdam UMC
Approved WMO Date:	11-04-2018
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	19-04-2018
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	23-10-2018
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	11-02-2019
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	05-04-2019
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	21-06-2019
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	02-07-2019
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	19-02-2020
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	06-03-2020
Application type:	Amendment

Review commission:	METC Amsterdam UMC
Approved WMO Date:	11-05-2020
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	17-07-2020
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	22-03-2021
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	03-05-2021
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	09-07-2021
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	30-09-2021
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	29-01-2022
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	02-03-2022
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	23-05-2022
Application type:	Amendment

Review commission:	METC Amsterdam UMC
Approved WMO Date:	15-06-2022
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	25-02-2023
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	13-03-2023
Application type:	Amendment
Review commission:	METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EudraCT	EUCTR2014-005139-14-NL
ClinicalTrials.gov	NCT02316106
CCMO	NL52170.029.15